WO2004031276A3 - Method of inducing maturation of dendritic cells and uses therefor - Google Patents

Method of inducing maturation of dendritic cells and uses therefor Download PDF

Info

Publication number
WO2004031276A3
WO2004031276A3 PCT/US2003/029454 US0329454W WO2004031276A3 WO 2004031276 A3 WO2004031276 A3 WO 2004031276A3 US 0329454 W US0329454 W US 0329454W WO 2004031276 A3 WO2004031276 A3 WO 2004031276A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
uses therefor
inducing maturation
maturation
inducing
Prior art date
Application number
PCT/US2003/029454
Other languages
French (fr)
Other versions
WO2004031276A8 (en
WO2004031276A2 (en
Inventor
Jian Li
Lamine Mbow
Theresa Goletz
David Peritt
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to EP03786513A priority Critical patent/EP1572228A4/en
Priority to AU2003295331A priority patent/AU2003295331A1/en
Publication of WO2004031276A2 publication Critical patent/WO2004031276A2/en
Publication of WO2004031276A8 publication Critical patent/WO2004031276A8/en
Publication of WO2004031276A3 publication Critical patent/WO2004031276A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/46444—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Abstract

The invention relates to the induction of responses relating to the maturation of dendritic cells, using IL-18 and IL-18 muteins, and compounds, compositions, methods of making and using thereof, including therapeutic methods and products.
PCT/US2003/029454 2002-09-19 2003-09-19 Method of inducing maturation of dendritic cells and uses therefor WO2004031276A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03786513A EP1572228A4 (en) 2002-09-19 2003-09-19 Method of inducing maturation of dendritic cells and uses therefor
AU2003295331A AU2003295331A1 (en) 2002-09-19 2003-09-19 Method of inducing maturation of dendritic cells and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41214502P 2002-09-19 2002-09-19
US60/412,145 2002-09-19

Publications (3)

Publication Number Publication Date
WO2004031276A2 WO2004031276A2 (en) 2004-04-15
WO2004031276A8 WO2004031276A8 (en) 2004-08-05
WO2004031276A3 true WO2004031276A3 (en) 2005-03-31

Family

ID=32069709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029454 WO2004031276A2 (en) 2002-09-19 2003-09-19 Method of inducing maturation of dendritic cells and uses therefor

Country Status (3)

Country Link
EP (1) EP1572228A4 (en)
AU (1) AU2003295331A1 (en)
WO (1) WO2004031276A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1793859E (en) 2004-08-20 2009-06-04 Smithkline Beecham Corp Treatment of oral and intestinal mucositis by administering human il-18
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790440B2 (en) * 2000-10-12 2004-09-14 Maxim Pharmaceuticals, Inc. Methods and compositions for promoting the maturation of monocytes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
EP2269629A3 (en) * 2000-05-11 2013-09-11 Baylor Research Institute Compositions and methods for producing antigen-presenting cells
CN1457258A (en) * 2000-06-02 2003-11-19 史密丝克莱恩比彻姆公司 Methods of treating viral diseases with IL-18 and IL-18 compositions
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
AU2002365269A1 (en) * 2001-10-26 2003-07-24 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2002951082A0 (en) * 2002-08-30 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic cellular agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790440B2 (en) * 2000-10-12 2004-09-14 Maxim Pharmaceuticals, Inc. Methods and compositions for promoting the maturation of monocytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARAJULI P. ET AL.: "Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets", EXP. HEMATOL., vol. 29, no. 10, October 2001 (2001-10-01), pages 1185 - 1193, XP002983908 *

Also Published As

Publication number Publication date
WO2004031276A8 (en) 2004-08-05
EP1572228A4 (en) 2009-03-04
AU2003295331A8 (en) 2004-04-23
EP1572228A2 (en) 2005-09-14
AU2003295331A1 (en) 2004-04-23
WO2004031276A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004080406A3 (en) Therapeutic compositions
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
HK1073653A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates and method of preparation
HK1082256A1 (en) New compounds, compositions and methods for treatment of inflammatory diseases and conditions
TW200510416A (en) P38 inhibitors and methods of use thereof
EP1622589A4 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2003251557A1 (en) Fat compositions for infant formula and methods therefor
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
GB0303609D0 (en) Novel therapeutic method and compositions
EP1578373A4 (en) Novel compositions and methods for the treatment of immune related diseases
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
WO2004031276A3 (en) Method of inducing maturation of dendritic cells and uses therefor
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2004021992A3 (en) Delivery of therapeutics to the brain and spinal cord
AU2003237150A1 (en) Compositions and methods for treating inflammatory connective tissue diseases
AU2002363228A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2004096848A8 (en) Novel composition and methods for the treatment of immune disorders
AU2002311623A1 (en) Process for the preparation of 1,4-dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents
EP1572130A4 (en) Compositions and methods for the treatment of immune related diseases
EP1594496A4 (en) Novel therapeutic method and compositions for topical administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 13/2004 CLASSEE 16/2004 REPLACE ""A1"" BY ""A2"" AND UNDER ""PUBLISHED"", REPLACE ""WITH INTERNATIONAL SEARCH REPORT"" BY ""WITHOUT INTERNATIONAL SEARCH REPORT""

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003786513

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003786513

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP